Home Featured Page 138

Featured

Latest

Serotonin, Synapses, and Setting: Gitte Moos Knudsen on the Neurobiology of Psychedelic Action

The Psychedelic Writers Guild’s Denver Mixer

The Mushroom Cure – Special Live Filming

Pα+ Psychedelic Bulletin #222: Unpacking EPIsoDE; Meta-Analysis Says Psychedelics No Better than Traditional Antidepressants; Usona’s First Patent Application Publishes

PsyBio Therapeutics Announces Non-Brokered Private Placement Financing

FILAMENT HEALTH ANNOUNCES NEW UNITED STATES PATENT ISSUANCES

Revive Therapeutics Ltd. Announces Offering of Up to $5 Million

Clearmind Announces Initiation of CMND-100 Manufacturing Program to Address its Upcoming...

Many Trips, Diminishing Returns: Cross-Tolerance Between LSD and DOI

PT375 – Microdosing & Citizen Science: Introducing the World’s First Take-Home...

Small Pharma to Participate in November Investor and Healthcare Conferences

Silo Pharma Initiates Study of Novel Joint Homing Peptide in Human...

Tryp Therapeutics Announces Poster Presentations on the Reduction of Chronic Pain...

Psychedelics Weekly – Bipartisan Political Movement & Psychedelics and Pain

EDITOR PICKS

Serotonin, Synapses, and Setting: Gitte Moos Knudsen on the Neurobiology of...

The Psychedelic Writers Guild’s Denver Mixer

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Quarterly Briefing: Q1 2026

Serotonin, Synapses, and Setting: Gitte Moos Knudsen on the Neurobiology of Psychedelic Action

The Psychedelic Writers Guild’s Denver Mixer

The Mushroom Cure – Special Live Filming

Pα+ Psychedelic Bulletin #222: Unpacking EPIsoDE; Meta-Analysis Says Psychedelics No Better than Traditional Antidepressants; Usona’s First Patent Application Publishes

PsyBio Therapeutics Announces Non-Brokered Private Placement Financing

FILAMENT HEALTH ANNOUNCES NEW UNITED STATES PATENT ISSUANCES

Revive Therapeutics Ltd. Announces Offering of Up to $5 Million

Clearmind Announces Initiation of CMND-100 Manufacturing Program to Address its Upcoming...

Many Trips, Diminishing Returns: Cross-Tolerance Between LSD and DOI

PT375 – Microdosing & Citizen Science: Introducing the World’s First Take-Home...

Small Pharma to Participate in November Investor and Healthcare Conferences

Silo Pharma Initiates Study of Novel Joint Homing Peptide in Human...

Tryp Therapeutics Announces Poster Presentations on the Reduction of Chronic Pain...

Psychedelics Weekly – Bipartisan Political Movement & Psychedelics and Pain

EDITOR PICKS

Quarterly Briefing: Q1 2026

Serotonin, Synapses, and Setting: Gitte Moos Knudsen on the Neurobiology of...

The Psychedelic Writers Guild’s Denver Mixer

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY